$1.35 Billion is the total value of Rock Springs Capital Management LP's 137 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $6,417,000 | -3.1% | 450,000 | -1.5% | 0.48% | -14.4% |
| PTI | Sell | PROTEOSTASIS THERAPEUTICS IN | $5,034,000 | +11.1% | 415,000 | -11.7% | 0.37% | -1.8% |
| INOV | Sell | INOVALON HLDGS INC | $1,878,000 | -76.3% | 104,302 | -75.6% | 0.14% | -79.0% |
| VRX | Sell | VALEANT PHARMACEUTICALS INTL | $1,331,000 | -40.8% | 66,100 | -22.7% | 0.10% | -47.3% |
| SPHS | Sell | SOPHIRIS BIO INC | $1,054,000 | +16.5% | 490,000 | -22.0% | 0.08% | +2.6% |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -35,000 | -100.0% | -0.06% | – |
| COO | Exit | COOPER COS INC | $0 | – | -47,600 | -100.0% | -0.61% | – |
| ANAC | Exit | ANACOR PHARMACEUTICALS INC | $0 | – | -177,500 | -100.0% | -0.80% | – |
| ANTM | Exit | ANTHEM INC | $0 | – | -121,000 | -100.0% | -1.41% | – |
| BXLT | Exit | BAXALTA INC | $0 | – | -810,000 | -100.0% | -2.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.